Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerrit Los

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Methods in Molecular Medicine|May 25, 2005
Gene expression profiling to characterize anticancer drug sensitivityJames K Breaux, Gerrit Los
Oncotarget|June 29, 2013
Targeting fibroblast growth factors in cancer: the key is what not to blockKevin P Baker, Gerrit Los
Expert Opinion on Therapeutic Targets|December 27, 2019
RSK2: a promising therapeutic target for the treatment of triple-negative breast cancerMy-My Huynh, Aarthi Jayanthan, Mary Rose Pambid, et al.
Expert Opinion on Investigational Drugs|September 2, 2020
The dawn of targeted therapies for triple negative breast cancer (TNBC): a snapshot of investigational drugs in phase I and II trialsMy-My Huynh, Mary Rose Pambid, Aarthi Jayanthan, et al.
Molecular Pharmacology|October 23, 2002
Identification of transdominant-negative genetic suppressor elements derived from hMSH2 that mediate resistance to 6-thioguanineMaida M de las Alas, Gerrit Los, Xinjian Lin, et al.
Cytometry|January 5, 2002
Using mRNA expression profiling to determine anticancer drug efficacyGerrit Los, Fei Yang, Goli Samimi, et al.
Cancer Chemotherapy and Pharmacology|September 21, 2004
cDNA microarray-based identification of genes and pathways associated with oxaliplatin resistanceGoli Samimi, Gerald Manorek, Rob Castel, et al.
Molecular Cancer Therapeutics|March 16, 2013
A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivoHidetoshi Kuruma, Hiroaki Matsumoto, Masaki Shiota, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 8, 2010
Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitorsAsima Mukhopadhyay, Ahmed Elattar, Aiste Cerbinskaite, et al.
BMC Genomics|August 2, 2012
Dose-dependent effects of small-molecule antagonists on the genomic landscape of androgen receptor bindingZhou Zhu, Manli Shi, Wenyue Hu, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Methods in Molecular Medicine|May 25, 2005
Gene expression profiling to characterize anticancer drug sensitivityJames K Breaux, Gerrit Los
Oncotarget|June 29, 2013
Targeting fibroblast growth factors in cancer: the key is what not to blockKevin P Baker, Gerrit Los
Expert Opinion on Therapeutic Targets|December 27, 2019
RSK2: a promising therapeutic target for the treatment of triple-negative breast cancerMy-My Huynh, Aarthi Jayanthan, Mary Rose Pambid, et al.
Expert Opinion on Investigational Drugs|September 2, 2020
The dawn of targeted therapies for triple negative breast cancer (TNBC): a snapshot of investigational drugs in phase I and II trialsMy-My Huynh, Mary Rose Pambid, Aarthi Jayanthan, et al.
Molecular Pharmacology|October 23, 2002
Identification of transdominant-negative genetic suppressor elements derived from hMSH2 that mediate resistance to 6-thioguanineMaida M de las Alas, Gerrit Los, Xinjian Lin, et al.
Cytometry|January 5, 2002
Using mRNA expression profiling to determine anticancer drug efficacyGerrit Los, Fei Yang, Goli Samimi, et al.
Cancer Chemotherapy and Pharmacology|September 21, 2004
cDNA microarray-based identification of genes and pathways associated with oxaliplatin resistanceGoli Samimi, Gerald Manorek, Rob Castel, et al.
Molecular Cancer Therapeutics|March 16, 2013
A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivoHidetoshi Kuruma, Hiroaki Matsumoto, Masaki Shiota, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 8, 2010
Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitorsAsima Mukhopadhyay, Ahmed Elattar, Aiste Cerbinskaite, et al.
BMC Genomics|August 2, 2012
Dose-dependent effects of small-molecule antagonists on the genomic landscape of androgen receptor bindingZhou Zhu, Manli Shi, Wenyue Hu, et al.
Pageof 3